Prevalence of polypharmacy and associated factors among patients living with HIV infection in Spain: The POINT study.

Autor: Morillo-Verdugo R; Pharmacy Department, Valme University Hospital, Sevilla, Spain., Sánchez-Rubio-Ferrández J; Pharmacy Department, Getafe University Hospital, Getafe, Spain., Gimeno-Gracia M; Pharmacy Department, Lozano Blesa University Clinical Hospital, Zaragoza, Spain., Robustillo-Cortés MLA; Pharmacy Department, Juan Ramón Jimenez Hospital, Huelva, Spain. Electronic address: aguasrobustillo@gmail.com., Almeida-González CV; Statistics and Research Methodology Unit, Valme University Hospital, Sevilla, Spain; Preventive Medicine and Public Health, Seville University, School of Medicine, Seville, Spain.
Jazyk: English; Spanish; Castilian
Zdroj: Enfermedades infecciosas y microbiologia clinica (English ed.) [Enferm Infecc Microbiol Clin (Engl Ed)] 2020 Nov 20. Date of Electronic Publication: 2020 Nov 20.
DOI: 10.1016/j.eimc.2020.09.020
Abstrakt: Purpose: Survival in people living with HIV (PLWH) has increased and thus people are aging with HIV, increasing the frequency of multimorbidity and polypharmacy. This cross-sectional study was conducted to evaluate the prevalence of polypharmacy among PLWH who were on antiretroviral treatment and were followed in an outpatient setting by the pharmacy department of several hospitals across Spain. In addition, we aimed to evaluate factors associated with polypharmacy and treatment complexity among this population.
Material and Methods: We recorded information on demographic data, data on disease control including viral load and CD4 count at the time of inclusion, comorbidities, pharmacologic treatment and drugs interactions. Polypharmacy was defined as the use of 6 or more different drugs, including antiretroviral medication; major polypharmacy was defined as the use of ≥11 different drugs.
Results: Overall, 1225 PLWH were eligible in the study. The median (IQR) age was 49 (40-54). Comorbidities were present in 819 (67%) PLWH and 571 (47%) had two or more comorbidities. Overall, 397 (32.4%, 95% CI 29.8-34.9) PLWH met the criteria for polypharmacy, and 67 (5.5%, 95% CI, 4.2-6.7) had major polypharmacy. Several factors were associated with polypharmacy such as type of antiretroviral treatment, presence of potential interactions, the use of several types of medications and the number of comorbidities. Treatment complexity was also a factor strongly associated with polypharmacy; for each point increase in the medication regimen complexity index (MRCI), the likelihood of polypharmacy increased 2.3-fold.
Conclusions: Polypharmacy is frequent among PLWH in Spain and contributes to a relevant extent to treatment complexity.
(Copyright © 2020 Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Publicado por Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: